UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
13.49
+0.38 (2.90%)
At close: Jun 27, 2025, 4:00 PM
13.69
+0.20 (1.48%)
After-hours: Jun 27, 2025, 7:50 PM EDT
UroGen Pharma Employees
UroGen Pharma had 235 employees as of December 31, 2024. The number of employees increased by 34 or 16.92% compared to the previous year.
Employees
235
Change (1Y)
34
Growth (1Y)
16.92%
Revenue / Employee
$390,940
Profits / Employee
-$589,068
Market Cap
621.99M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
URGN News
- 12 days ago - URGN SHAREHOLDER REPORT: UroGen Pharma Ltd. was Sued for Fraud – Investors with Losses are Notified to Contact BFA Law by July 28 Court Deadline (NASDAQ:URGN) - GlobeNewsWire
- 13 days ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen - PRNewsWire
- 15 days ago - UroGen Pharma: Lessons Learned And Future Outlook - Seeking Alpha
- 15 days ago - SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen - GlobeNewsWire
- 15 days ago - U.S. FDA Approves UroGen's ZUSDURI™ (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) - Business Wire
- 16 days ago - US FDA approves Urogen's bladder cancer drug - Reuters
- 18 days ago - UroGen: Despite ODAC Vote, Hope Remains With Targeting Of Other Cancer Subpopulation - Seeking Alpha
- 18 days ago - URGN LEGAL NOTICE: Lose Money when UroGen Pharma Ltd. Stock Plummeted 45%? - GlobeNewsWire